Quarterly ResultMay 13, 2026, 07:37 AM
Arbutus Q1 Revenue $179.1M, Net Income $169.7M; Imdusiran Gets Fast Track
AI Summary
Arbutus Biopharma Corporation reported strong first quarter 2026 financial results, driven by an estimated $178.7 million in license revenue from Genevant related to the Moderna litigation settlement. The company posted a net income of $169.7 million, a significant turnaround from a net loss in the prior year. Additionally, the FDA granted Fast Track designation to imdusiran for the treatment of chronic hepatitis B, potentially accelerating its development and review.
Key Highlights
- Q1 2026 total revenue was $179.1 million, up from $1.8 million in Q1 2025.
- Net income for Q1 2026 was $169.7 million, or $0.88 per basic share, compared to a net loss of $24.5 million in Q1 2025.
- Arbutus expects to receive an estimated $178.7 million in July 2026 from the Moderna litigation settlement.
- Cash, cash equivalents, and marketable securities totaled $95.2 million as of March 31, 2026.
- FDA granted Fast Track designation for imdusiran for chronic hepatitis B in April 2026.
- Research and development expenses decreased to $4.1 million in Q1 2026 from $9.0 million in Q1 2025 due to cost savings.
- General and administrative expenses were $5.9 million in Q1 2026, slightly up due to higher legal fees from the Moderna settlement.
Price Impact
More from ABUS